International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMontefiore Medical Center

About this trial

This multicenter retrospective cohort study aims to evaluate and compare the technical performance, safety, and clinical outcomes of intracranial aneurysms treated with flow diverter stents and endosaccular flow disruptors.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Consecutive adult patients (18 years of age or older)

Complete medical records and follow-up data available

Disqualifiers

Incomplete procedural or follow-up records

Non-flow-diverter or non-flow-disruptor treatments (e.g., coiling-only cases)

Aneurysms treated with investigational devices not listed within Inclusion Criteria

Trial population

Patients with intracranial aneurysms who underwent endovascular treatment with flow diverter stents or endosaccular flow disruptors

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

5,000 Participants
are grouped into 2 trial groups
Group A: Endoluminal Flow Diverter Stent
Group B: Intrasaccular Flow Disruptor

Trial outcomes

Primary outcomes

1

Technical Success

Technical Success will be determined by successful deployment of the flow diverter stent or endosaccular flow disruptors. A dichotomous determination (i.e., Yes/No) will be made and summarized for this study.

Time frame
Periprocedurally, up to 24 hours
2

Procedural Complications following placement

Procedural complications will be identified as the number of instances of the following adverse clinical events: In-stent Thrombosis/Stenosis; Ischemic complications (Transient Ischemic Attack/Stroke), Intracerebral hemorrhage, Aneurysm rupture, and Vessel occlusion due to flow diverter stent or endosaccular flow disruptor placement.

Time frame
From the time of the procedure up to 1 month post treatment
3

Clinical Outcomes at Discharge

Clinical outcomes at discharge will be assessed using the modified Rankin Scale (mRS) for neurologic disability. The mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome.

Time frame
Upon study discharge, up to 4 weeks
4

Clinical Outcomes at last available Follow-up

Clinical outcomes at last available follow-up will be assessed using a variant of the modified Rankin Scale (mRS) for neurologic disability. The classic mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome. Scoring will also include a 6 to identify patients who have expired.

Time frame
Up to 24 months post procedure

Secondary outcomes

1

Radiation Exposure

Radiation exposure over the course of the procedure will be extracted and summarized. Radiation exposure will be evaluated based on relevant imaging system metrics used to calculate the total radiation dose delivered to the patient based on the fluoroscopy time and the area of the X-ray field exposed during the procedure. Flow diverter stents and endosaccular flow disruptors typically result in significantly lower radiation exposure compared to other endovascular techniques for treating brain aneurysms due to a reduction in fluoroscopy time and overall reduced radiation dose due to the streamlined nature of the procedures.

Time frame
Periprocedurally, up to 4 hours
2

Procedure Duration

The duration of procedure placement will be extracted and summarized. The duration of the procedure is influenced by the complexity of the aneurysm, the patient's anatomy, and the experience of the interventional radiologist and care team. Shorter procedure duration times are associated with more favorable outcomes.

Time frame
Periprocedurally, up to 4 hours
3

Use of Adjunct Devices

The use of adjunctive devices such as coils, stents or balloons to further enhance aneurysm occlusion of the flow diverter stent or to facilitate positioning and deployment of the endosaccular flow disruptor within the aneurysm sac during the procedure will be extracted and summarized. The number of adjunct devices will be extracted and summarized.

Time frame
Periprocedurally, up to 4 hours
4

Recurrence of Aneurysm

The percentage of patients who experienced aneurysm recurrence will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to recurrence will be assessed and summarized.

Time frame
6 to 24 months post procedure

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Montefiore Medical Center

Lead sponsor

Mayo Clinic

Collaborator

Sarasota Memorial Health Care System

Collaborator

Geisinger Health

Collaborator

University at Buffalo

Collaborator

Thomas Jefferson University

Collaborator

University Health Network, Toronto

Collaborator

Munson Medical Center

Collaborator

HCA Houston Healthcare Kingwood

Collaborator

University of Miami

Collaborator

Robert Wood Johnson University Hospital

Collaborator

Lahey Hospital & Medical Center

Collaborator

Unity Health Toronto

Collaborator

Allina Health System

Collaborator